Novel rational drug design and phage display technologies combined with chemical and genetic modification techniques allow for the large-scale production of peptide and peptidomimetic drug candidates with enhanced stability and physiological activity.163 Nonetheless, further investigations of VCAM-1 protein structure and interactions during atherosclerosis are necessary to optimize the pharmacodynamic properties of future peptide therapies. The gene discussed is VCAM1; the disease is atherosclerosis.